A Phase II trial testing vibecotamab, a CD123-targeting bispecific antibody, reported high response rates in myelodysplastic syndromes after hypomethylating agent failure. However, the same study found limited clearance in residual acute myeloid leukemia, highlighting a differential activity profile across related myeloid disease stages. The trial’s design makes the signal clinically relevant: CD123 is a shared target across myeloid malignancies, but response depth and durability can diverge depending on the disease’s maturation and biology. The reported results suggest vibecotamab may be particularly effective in higher-risk MDS settings rather than reliably driving deep eradication in AML residual disease. The next steps will likely involve refining patient selection and exploring combination approaches to improve outcomes in AML contexts where residual disease clearance remains a challenge.
Get the Daily Brief